GridAI Technologies Reports $3.4 Million Net Loss in Q1 2026, First Revenue Since Acquisition

GridAI Technologies Corp., formerly known as Entero Therapeutics, Inc., reported its financial results for the first quarter of 2026, revealing a net loss of approximately $3.4 million, a significant increase from a net loss of $1.3 million in the same period last year. The company generated revenue of $38,208, marking its first revenue since the acquisition of Grid AI Corp. in September 2025, which has shifted the company’s focus towards artificial intelligence-driven energy technology. The increase in net loss is attributed to higher operating expenses, which rose to $3 million from $821,386 in the prior year, primarily due to increased research and development costs and general administrative expenses associated with the integration of Grid AI.

The company’s total operating expenses for the quarter included $631,380 in research and development expenses, a substantial increase from $15,827 in the previous year, reflecting the costs associated with the new AI segment. General and administrative expenses also surged to $2.4 million from $805,559, driven by costs related to the acquisition, public company expenses, and increased professional fees. The company’s gross loss for the quarter was $613,740, with costs of services amounting to $651,948.

In terms of financial position, GridAI reported cash and cash equivalents of $385,542 as of March 31, 2026, down from $899,784 at the end of 2025. The company’s total assets decreased to $47.97 million from $48.55 million, while total liabilities increased to $20.47 million from $19.72 million. The increase in liabilities was primarily due to higher accounts payable and accrued expenses. The company’s accumulated deficit also grew to approximately $212.1 million, raising concerns about its ability to continue as a going concern without additional capital.

Strategically, the company has undergone significant changes, including the rescission of its acquisition of ImmunogenX, which was completed on December 31, 2025. This decision eliminated the associated liabilities and allowed the company to focus on its core operations in AI-driven energy technology and the development of its remaining biopharmaceutical asset, Adrulipase. The company is actively exploring various funding options to support its operations and has indicated that it may pursue additional equity or debt financing, strategic partnerships, or asset sales to improve its liquidity.

Looking ahead, GridAI Technologies Corp. anticipates continued losses as it integrates its new operations and develops its technology platforms. The company remains focused on advancing its AI-driven energy solutions while managing its legacy biopharmaceutical activities. The outlook remains uncertain, with the company emphasizing the need for additional capital to sustain its operations and execute its business plan effectively.